Results from two studies show that treatment with the novel kinase inhibitor nintedanib significantly slowed disease progression in patients with idiopathic pulmonary fibrosis (IPF). However, only one study showed nintedanib had any effect on slowing deterioration in quality of life or reducing the risk of a first acute exacerbation compared with placebo.
Patients with schizoaffective disorder who were treated with paliperidone palmitate (as monotherapy and adjunctive therapy) experienced delayed time to relapse and reduced risk of relapse compared to patients treated with placebo.
Adult patients with binge eating disorder who were treated for 12 weeks with lisdexamfetamine dimesylate reported having 4 fewer binge days per week, and also experienced improvements in weight and triglyceride levels.
Patients in a trial of a first-in-class medication for the treatment of female sexual dysfunction reported improvement in overall sexual function, including an increase in the number of satisfying sexual events, and a concomitant decrease in distress levels associated with sexual dysfunction.
Patients with celiac disease treated with larazotide acetate experienced improvements in GI symptoms and non-GI symptoms such as headache and fatigue, as well as significant reductions in the number of symptomatic days.
Study results presented at the 2014 annual meeting of the American Psychiatric Association show that a reduced dosage of the antidepressant vilazodone is as effective as the currently approved dosage.
Study results presented at the 2014 APA annual meeting show patients treated with vortioxetine significant improvement in composite cognition scores compared to patients treated with placebo, independent of the drug's effect on their depression symptoms.
Results from a six-week study show patients with major depressive disorder treated with brexpiprazole had significantly reduced risk of akathisia and other side effects.
Though constipation as a side effect of opioid therapy is generally considered a tolerability issue that can be treated with over-the-counter laxatives, opioid-induced constipation may still lead to serious gastrointestinal complications.
Boys with Duchenne muscular dystrophy saw continued and significant clinical improvement in motor function tests after 96 weeks of administration of investigational drug eteplirsen.
Scientists studying patients with chronic pain have uncovered four specific genes that are associated with pain perception.
Study results to be presented at the 2014 AAN annual meeting show asymptomatic carotid stenosis may also contribute to impaired memory, cognitive function, and decision making.
Several studies have shown good results with Roux-en-Y gastric bypass and laparoscopic gastric banding when combined with lifestyle modifications in severely overweight patients with type 2 diabetes.
Mitigating the risk of stroke, heart failure, and death when treating patients with atrial fibrillation requires a careful consideration of patient characteristics and management options.
SAPPHIRE II trial results show sustained virologic response in 96% of treatment-experienced patients with genotype 1 hepatitis C who were treated with interferon-free, triple-drug regimen.
Study results presented at ACC.14 show treatment with PCSK9 inhibitor evolocumab significantly reduces LDL-cholesterol levels in patients with hypercholesterolemia.
Successful applications of nanotechnology in the field of immunology will enable new generations of vaccines, adjuvants, and immunomodulatory drugs that aim to improve clinical outcomes in response in a range of infectious and non-infectious diseases.
With reimbursement increasingly tied to quality measures and other metrics, the question of whether best practices actually produce improved outcomes has taken on greater importance for clinicians and their patients.
New research suggests that patients with allergic rhinitis face significantly lower risks for heart attacks, cerebrovascular disease, and all-cause mortality.
Although there appears to be no difference in blood pressure reduction in patients who take aspirin at bedtime compared to those who take it when they awake in the morning, bedtime aspirin may be associated with reduced morning platelet reactivity.
Patients with heart failure who received left ventricle augmentation with Algisyl-LVR hydrogel implant experienced improved quality of life and functional capacity compared to similar patients treated with optimal medical therapy.
Treating Hispanic patients with stable CAD with daily low-dose aspirin plus ticagrelor provided lower levels of on-treatment platelet reactivity with a faster onset and greater extent of platelet inhibition, compared to treatment with aspirin plus clopidogrel.
Creating a safer environment for clinicians and patients starts with better formalized reporting of aggressive and violent behavior, and should also include more rigorous screening and assessment for risk markers of violent behavior.
A recent anonymous survey among nephrologists suggests that patients' social support, ability to understand the transplant process, and age are the most important factors influencing nephrologists' decisions to exclude them from kidney transplant referral.
In his presentation, George Therapondos, MD, a hepatologist at the Ochsner Medical Center, detailed how to manage inpatients with cirrhosis that progresses to liver failure and gastrointestinal bleeding.
Patients who have chronic kidney disease (CKD) and end-stage renal disease (ESRD) require 20% less warfarin and more monitoring for bleeding than patients who have normal kidney function.
Primary prevention measures for upper GI bleeding should include NSAIDs, antiplatelet therapy, and anticoagulants appropriately, while secondary preventive measures should include testing and treating H. pylori and using long-term PPIs when appropriate.
Results of a recent community-based study suggest that African-American patients are at higher risk for acute kidney injury (AKI) than Caucasians - a difference that appears to be related to disparities in income and socioeconomic status.
Watchful waiting in patients with chronic hepatitis C (HCV) genotype 1 infection may increase the number of advanced liver disease cases, according to a poster presented at the 2013 American Association for the Study of Liver Disease (AASLD) meeting held in Washington, DC.
Plenary session at CHEST 2013 focused on the impact of early warning scores, medical response teams, availability of critical care attending intensivists, and other quality measures in intensive care.